ADAM17 and hepatocellular carcinoma: ADAM17, a known ectodomain sheddase of epidermal growth factor receptor (EGFR) ligands such as heparin-binding epidermal growth factor-like growth factor (HB-EGF), has been reported to enhance actin cytoskeletal remodelling at the tip of the lamellipodium in hepatocellular carcinoma (HCC) cells [21,22].